2007年11月10日 · Research published in the medical journal Lancet estimates that 88,000 Americans had heart attacks from taking Vioxx, and 38,000 of them died. Shortly before the FDA approved Vioxx in 1999,...

Merck & Co. announced Sept. 30 a voluntary worldwide withdrawal of rofecoxib (Vioxx) after a study showed patients taking the drug on a long-term basis face twice the risk of a heart attack compared with patients receiving placebo.

Rofecoxib was approved in the US by the US Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablets and as an oral suspension.

SEPTEMBER 30, 2004, Merck & Co. withdrew its blockbuster arthritis med-ication rofecoxib (Vioxx) from the market after the drug was found to increase the risk of myocardial infarction (MI) and stroke.

2004年10月6日 · On September 30, 2004, Merck and Co. Inc., the manufacturer of the arthritis drug rofecoxib (Vioxx), announced the worldwide voluntary market withdrawal of rofecoxib after a study confirmed long-standing concerns that use of the drug raises the risk ...

2004年10月1日 · That trial was stopped immediately because data showed that patients taking VIOXX had an increased risk for confirmed cardiovascular events, such as heart attack and stroke, beginning after 18 months of treatment. VIOXX was launched in the United States in 1999 and has been marketed in more than 80 countries.

2009年3月2日 · After publication of the VIGOR (Vioxx Gastrointestinal Outcomes Research) study and the revelation of a 4- to 5-fold increased risk of cardiovascular events in subjects using Vioxx compared with those using the NSAID naproxen, the FDA asked Merck whether the Data Safety Monitoring Board (DSMB) for an ongoing trial of Vioxx used to prevent ...

2005年5月5日 · Documents released Thursday at a congressional hearing detail how a sales army of 3,000 turned the drug into a multibillion-dollar blockbuster before it was pulled from the market last fall because...

Vioxx is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). Vioxx is also related to the nonselective NSAIDs , such as ibuprofen and naproxen. Vioxx is a prescription medicine...

2015年4月24日 · Vioxx (Rofecoxib) a nonsteroidal anti-inflammatory drug (NSAID) was introduced to the market in 1999. In 1994, Merck’s R&D program discovered Vioxx, one of a group COX-2 inhibitors, COX-2 inhibitors include over the counter medications such as Advil (ibuprofen) and Aleve (naproxen) that serve to reduce both pain and inflammation.